Cefuroxime

Summary

Cefuroxime (CHEMBL1436) is an approved small molecule (ATC J01DC02); indicated across 6 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DC02 (+1 more)
• Indications: 6 conditions
• Clinical trials: 40
• Chemistry: 424.4 Da · C16H16N4O8S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1436
Name	Cefuroxime
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5479529
ChEBI	CHEBI:3515
ATC	J01DC02, S01AA27
Molecular formula	C16H16N4O8S
Molecular weight	424.4
InChIKey	JFPVXVDWJQMJEE-IZRZKJBUSA-N

SMILES: CO/N=C(/C1=CC=CO1)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O

IUPAC name: (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2Z)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.

Pharmacological roles (ChEBI): drug allergen.

Also known as: 640/359, Cefuroxima, Cefuroxime, Cefuroxime acid, Cefuroximine, cefuroxime, cefuxoxime, CEFUROXIME, Cefuroxim, Cefuroxime sodium

Parent form; salt/anhydrous children: CHEMBL2146124

Patent coverage: 156 distinct patent families (277 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Progesterone receptor, Nuclear receptor subfamily 1 group I member 2.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 3 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	5.41	AC50	3900	nM	CHEMBL_ACT_25222309
NR1I2	5.21	AC50	6100	nM	CHEMBL_ACT_25188347

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
pneumonia	3	MONDO:0005249	EFO:0003106
appendicitis	2	MONDO:0005649	EFO:0007149
endophthalmitis	1	MONDO:0016047	MONDO:0016047

Clinical trials

Total trials: 40.

Phase distribution

Phase	Trials
PHASE4	16
Not specified	14
PHASE2	5
PHASE3	2
EARLY_PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05784311	PHASE4	RECRUITING	Standard Versus Prolonged Antibiotic Prophylaxis After Pancreatoduodenectomy (SPARROW)
NCT06527560	PHASE4	RECRUITING	Clinical Trial Comparing Oral Versus Intravenous Cefuroxime in Pregnant Women with Pyelonephritis
NCT06709196	PHASE4	RECRUITING	Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
NCT00497341	PHASE4	COMPLETED	Antibiotic Prophylaxis in Total Knee Prosthesis
NCT00530400	PHASE4	COMPLETED	Study of the Efficacy of Preoperative Cefuroxime Prophylaxis to Prevent Surgical Site Infection in Herniated Disk Surgery
NCT00613769	PHASE4	COMPLETED	Orally Administered Trimethoprim-sulfamethoxazole and Metronidazole as Prophylaxis of Infection Following Elective Colorectal Surgery
NCT00901628	PHASE4	COMPLETED	Periarticular Multimodal Drug Injections in Total Knee Arthroplasty
NCT01080963	PHASE4	COMPLETED	Daptomycin as Antibiotic Prophylaxis of Sternal Wound Infections
NCT01138852	PHASE4	COMPLETED	Ampicillin/Sulbactam Versus Cefuroxime as Antimicrobial Prophylaxis for Cesarean Section
NCT01659866	PHASE4	COMPLETED	Antibiotic Prophylaxis for Transrectal Prostate Biopsy
NCT02009098	PHASE4	WITHDRAWN	RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section
NCT02072798	PHASE4	COMPLETED	Antibiotics and Gut Microbiota Among Newborn Infants
NCT02505581	PHASE4	COMPLETED	Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis
NCT03141476	PHASE4	COMPLETED	Adequacy of Perioperative Cefuroxime Dosage According to the BMI
NCT04161599	PHASE4	UNKNOWN	Preoperative Oral Antibiotics With vs Without Mechanical Bowel Preparation to Reduce Surgical Site Infections Following Colonic Resection: an International Randomized Controlled Trial.
NCT04303390	PHASE4	COMPLETED	24 Vs 48 Hours of Cefazolin or Cefuroxime as Prophylaxis
NCT00648726	PHASE3	COMPLETED	An Open, Prospective, Randomized, Multicenter Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin Versus Cefuroxime Alone or With Oral Erythromycin for the Treatment of Chinese Patients Who Were Hospitalized for Pneumonia
NCT01524081	PHASE3	COMPLETED	Antibiotic Prophylaxis in the Prevention of Surgical Site Infections After Selected Urgent Abdominal Surgical Procedures
NCT05609240	PHASE2	RECRUITING	Colo-Pro_2: Bolus-continuous Infusion Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery
NCT06406114	PHASE2	RECRUITING	Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
NCT07492134	PHASE2	NOT_YET_RECRUITING	APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)
NCT02445859	PHASE2	COMPLETED	Continuous Antibiotic Prophylaxis in Colorectal Surgery
NCT04212078	PHASE1/PHASE2	UNKNOWN	Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime
NCT05398081	PHASE2	COMPLETED	Cefuroxime vs Ceftriaxone for SSI Prevention in Neurosurgery
NCT02789579	EARLY_PHASE1	UNKNOWN	The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy
NCT04479657	EARLY_PHASE1	UNKNOWN	Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection
NCT05337566	Not specified	RECRUITING	Does Additional Use of Preoperative Azithromycin Decrease Posthysterectomy Infections
NCT05750966	Not specified	ACTIVE_NOT_RECRUITING	Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis
NCT07346742	Not specified	RECRUITING	Prevention of Surgical Site Infection in Open Paediatric Groin Surgeries Using Intravenous Prophylactic Antibiotics and Antimicrobial-coated Sutures
NCT00136344	Not specified	COMPLETED	Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery
NCT00162604	Not specified	UNKNOWN	Prophylactic Antibiotic Treatment During Vaginal Repair
NCT00355602	Not specified	COMPLETED	Antibiotics for the Treatment of Ulcerative Colitis
NCT00730938	Not specified	COMPLETED	The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery
NCT01237730	Not specified	UNKNOWN	Tailored Antibiotics Prophylaxis for Percutaneous Endoscopic Gastrostomy
NCT01372371	Not specified	UNKNOWN	Efficacy of Local Powder Prophylactics
NCT01434173	Not specified	COMPLETED	Risk of Acute Liver Injury in Users of Antimicrobials
NCT02800785	Not specified	COMPLETED	The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial
NCT02850250	Not specified	WITHDRAWN	Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery
NCT04470973	Not specified	UNKNOWN	Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.
NCT05388747	Not specified	UNKNOWN	Population Pharmacokinetics, Effectiveness and Safety of Cefuroxime in Neonates

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).